FMP
Enter
Data
Fundamental StatementsForm 13FInsider & Congressional TradingAnalyst Estimates & Price TargetHistorical Market DataReal-Time WebSocketESG DataForex Market DataETF & Mutual FundCommodity Market DataIndex Market DataAdvanced Market MetricsEconomics DataSearch & DirectoryCrypto DataEarnings Call TranscriptsMarket CalendarCompany Profile
API Tools
Extras
2seventy bio, Inc.
TSVT
NASDAQ
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
5 USD
0 (0%)
WACOC
Price
5
Beta
Diluted Shares Outstanding
52.22M
Costof Debt
4
Tax Rate
After Tax Cost Of Debt
4
Risk Free Rate
Market Risk Premium
Cost Of Equity
Total Debt
243.72M
Total Equity
261.09M
Total Capital
504.81M
Debt Weighting
48.28
Equity Weighting
51.72
Wacc
6.53
